Kriya Raises $313 Million to Advance Gene Therapy Programs
Kriya Therapeutics has secured $313.3 million in new financing, according to a recent SEC filing. The filing did not outline neither the planned use of the funds, nor the names of the investors, specifying only that two parties contributed.
The North Carolina– and California-based company is developing single-dose gene therapies across ophthalmology, neurology, and metabolic diseases. Its pipeline includes treatments for geographic atrophy, thyroid eye disease, trigeminal neuralgia, focal epilepsy, type 1 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).
The company is backed by investors including Patient Square Capital, Foresite Capital, Bluebird Ventures, Amplo, Woodline Partners, Narya, QVT Financial, CAM Capital, and the T1D Fund, among others.
Image credit: Kriya Therapeutics Pipeline Kriya’s leading programs include:
KRIYA-825 – for Geographic Atrophy
- Key objectives: Slow lesion growth, preserve vision, provide multi-year durability
KRIYA-586 – for Thyroid Eye Disease
- Key objectives: Reduce proptosis and diplopia, enable localized durable effect, minimize systemic toxicity
KRIYA-839 – for Type 1 Diabetes
- Key objectives: Achieve insulin independence, improve glycemic control, reduce daily injection burden
KRIYA-497 – for MASH (Metabolic Dysfunction-Associated Steatohepatitis)
- Key objectives: Anti-fibrotic activity, reverse steatosis, durable metabolic benefit
KRIYA-748 – for Trigeminal Neuralgia
- Key objectives: Reduce pain attacks, provide long-term durability, allow control via drug withdrawal
KRIYA-382 – for Focal Epilepsy
- Key objectives: Reduce seizures, provide multi-year durability, reversible “on-off” control
Kriya’s geographic atrophy candidate KRIYA-825 has advanced through IND-enabling studies and is moving toward clinical evaluation. In neurology, KRIYA-748 for trigeminal neuralgia has also reached late preclinical development, with preclinical evidence supporting its targeted ion channel approach. Other programs, including therapies for type 1 diabetes, MASH, and focal epilepsy, remain in earlier stages of research and development.
The $313 million raise places Kriya among the largest biotech financings of 2025, behind rounds by Isomorphic Labs ($600 million in March), Verdiva Bio ($411 million in January), and others.
Topic: Biotech Ventures
